A Sequential 2 Arm Open Label Study to Evaluate the Effects of Encorafenib in Combination with Binimetinib In Patients with BRAF V600 Mutant Unresectable or Metastatic Melanoma or Other Advanced Solid Tumors (Array-818-103)

A Sequential 2 Arm Open Label Study to Evaluate the Effects of Encorafenib in Combination with Binimetinib In Patients with BRAF V600 Mutant Unresectable or Metastatic Melanoma or Other Advanced Solid Tumors (Array-818-103)

Trial Category:
Other Solid Tumor
Phase
I
Contact(s)
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Location(s)
Methodist Estabrook Cancer Center, Omaha, NE

This study is looking at new drugs for metastatic or unresectable Melanoma and other solid tumors.

 
 
Become a NOS Member Today!
 

Platinum Corporate Members

Gold Corporate Members